Uromigos Live 2023 - RCC RT
Advertisement
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
The panel shared their approach to treatment selection for clear cell kidney cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.